Eaton Vance Management’s NovoCure NVCR Stock Holding History

Eaton Vance Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.74M	Buy	36,093 +1,454	+4%	+$113K	﹤0.01%	950
2022 Q2	$2.41M	Sell	34,639 -76	-0.2%	-$5.72K	﹤0.01%	1022
2022 Q1	$2.88M	Buy	34,715 +20,611	+146%	+$1.52M	﹤0.01%	1064
2021 Q4	$1.06M	Sell	14,104 -48	-0.3%	-$4.82K	﹤0.01%	1167
2021 Q3	$1.62M	Buy	14,152 +123	+0.9%	+$18.6K	﹤0.01%	974
2021 Q2	$3.11M	Buy	14,029 +29	+0.2%	+$5.64K	﹤0.01%	905
2021 Q1	$1.85M	Buy	14,000 +6	+0%	+$949	﹤0.01%	994
2020 Q4	$2.42M	Sell	13,994 -18	-0.1%	-$2.46K	﹤0.01%	885
2020 Q3	$1.56M	Hold	14,012	–	–	﹤0.01%	900
2020 Q2	$831K	Hold	14,012	–	–	﹤0.01%	999
2020 Q1	$944K	Hold	14,012	–	–	﹤0.01%	918
2019 Q4	$1.18M	Hold	14,012	–	–	﹤0.01%	942
2019 Q3	$1.05M	Buy	+14,012	New	+$1.12M	﹤0.01%	946

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eaton Vance Management's NVCR Position: Q3 2022 in Review

Eaton Vance Management increased its NovoCure (NVCR) stake by 4.2% in Q3 2022, buying an estimated $113K and bringing the position to 36,093 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Eaton Vance Management first reported a position in NVCR in Q3 2019 and has held it in 13 quarters since. The position peaked at $3.11M in Q2 2021. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Eaton Vance Management held 36,093 shares of NovoCure worth $2.74M as of Q3 2022.
Eaton Vance Management bought 1,454 NovoCure shares in Q3 2022, an estimated $113K.
NovoCure made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #950 holding.
Eaton Vance Management first reported a position in NovoCure in Q3 2019 and has held it in 13 quarters since.
Eaton Vance Management's NovoCure position peaked at $3.11M in Q2 2021.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.